Stock Price Forecast

May 31, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Acasti Pharma Inc chart...

About the Company

Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for patients with severe HTG.

CEO

Janelle D'Alvise

Exchange

NASDAQ

Website

www.acastipharma.com

$-2M

Total Revenue

3

Employees

$23M

Market Capitalization

-2.27

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ACST News

Closing Bell: Acasti Pharma Inc up on Monday (ACST)

12h ago, source: The Globe and Mail

Today during trading, Acasti Pharma Inc shares closed at $0.58 after opening the day at $0.56. It traded at a low of $0.56 to a high of $0.58. Share prices gained 1.75 percent from the previous day's ...

Acasti Pharma, Inc. Class A Common Stock (ACST)

8y ago, source: Nasdaq

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...

Acasti Pharma Inc.

1mon ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

14d ago, source: Morningstar

LAVAL, QC, May 17, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that ...

Acasti Pharma, Inc. (ACST) stock forecast and price target

1y ago, source: Yahoo Finance

Find the latest Acasti Pharma, Inc. ACST analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Acasti Pharma Provides Update on Recent Financing Activities

2y ago, source: ADVFN

As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) is providing an update on the use of its “at ...

Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package

1mon ago, source: ADVFN

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription ...

Acasti Pharma Celebrates Rare Disease Day

21d ago, source: Yahoo Lifestyle Singapore

LAVAL, Québec, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today recognizes and celebrates Rare Disease Day (February 28), as ...

Closing Bell: Acasti Pharma Inc up on Monday (ACST)

15d ago, source: The Globe and Mail

In market activity today, Acasti Pharma Inc opened at $0.56 and closed at $0.58. prices ranged from $0.56 to $0.58. Shares raised 1.75 percent from the previous day's close of $0.57. During the ...

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

14d ago, source: Yahoo Finance

LAVAL, QC, May 17, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...